



EFSA premises, Parma (IT), 27 & 28 September 2023

Draft agenda

Day 1

08:30- 09:00	Registration			
OPENIN	OPENING CEREMONY			
09:00- 09:30	Welcome and introduction to the event by the EFSA Chief Scientist	Carlos das Neves, EFSA		
	Recorded message from the Food and Drug Administration Commissioner	Robert M. Califf M.D., FDA (US)		
	Welcome from FDA	Tucker Patterson, FDA (US)		
SESSION 1 NAMs Global Landscape Co-chairs: Tucker Patterson, National Center for Toxicological Research (NTCR, FDA) (US) & Georges Kass, EFSA				
09:30- 09:40	Opening Remarks	Co-chairs		
09:40- 10:10	Technology for future smart food Q&A	Kristi Muldoon Jacobs, FDA (US)		
10:10- 10:40	ToxAIcology – AI is the future of toxicology Q&A	Thomas Hartung, Center for Alternatives to Animal Testing (CAAT) (US)		
10:40- 11:10	Coffee/Tea break	4		
11:10- 11:40	Bridging the divide between scientific development and regulatory application Q&A	Maurice Whelan, European Commission (EC, JRC)		
11:40- 12:10	The Scientific Progress of Drug Regulation in China and its Regulatory Science Development Q&A	Junning Zhao, National Medical Products		







		Administration (NMPA) (CN)
12:10- 12:40	NIHS 150th Anniversary and Regulatory Sciences Q&A	Masamitsu Honma, National Institute of Health Sciences (NIHS) (JP)
12:40- 14:00	Networking lunch	
	N 2 NAMs: Regulatory implementations rs: Suzanne Fitzpatrick, FDA (US) & Calvin Yeo, Singapore Foo	d Agency (SFA) (SG)
14:00- 14:10	Opening Remarks	Co-chairs
14:10- 14:30	Implementation of the 3RS at the EMA: past, present and future Q&A	Sonja Beken, FAGG/AFMPS & Chair 3Rs Working Party, European Medicines Agency (EMA)
14:30- 14:50	Toxicokinetics Modeling Q&A	James Chan, A*STAR, Singapore Institute of Food and Biotechnology Innovation (SG)
14:50- 15:10	Activities of the Japanese Center for the Validation of Alternative Methods (JaCVAM), NIHS: Development of new toxicity tests using NAM and their use in regulations Q&A	Yoko Hirabayashi, National Institute of Health Sciences (NIHS) (JP)
15:10- 15:30	Regulatory landscape and critical Needs for NAMs in the Hazard assessment of industrial chemicals Q&A	Mounir Bouhifd, European Chemicals Agency (ECHA)
15:30- 15:50	Emerging technologies for protein safety Q&A	Anna Lanzoni, EFSA
15:50- 16:10	Coffee/Tea break	
Co-chaiı	N 3 Regulatory Apps rs: Joanne Chan, Singapore Food Agency (SFA) (SG) & Catheri spection Agency (CFIA) (CA)	ne Carrillo, Canadian
16:10- 16:20	Opening Remarks	Co-chairs
16:20- 16:40	Evaluation for developmental toxicity using human iPS cells Q&A	Yusuke Okubo, National Institute of Health Sciences (NIHS) (JP)







16:40- 17:00	Quality attributes and standards for mRNA-based and Lipid-based therapeutics Q&A	Luigi Calzolai, European Commission (EC, JRC)
17:00- 17:20	How to handle human variability in risk assessment Q&A	Bob van der Water, University of Leiden (NL)
17:20- 17:40	Case studies on refining risk assessment of food-related substances with NAMs Q&A	Takashi Yamada, National Institute of Health Sciences (NIHS) (JP)
17:40- 18:00	FDALabel: A tool to facilitate regulatory application of drug labeling at FDA Q&A	Hong Fang, NCTR, FDA (US)
18:00- 18:15	Wrap-up of day 1	Guilhem de Seze
18:15- 20:15	Poster session & Networking cocktail	





Day 2

08:00- 08:30	Registration		
SESSION 4 Emerging Technologies Co-chairs: Laila Mouawad, Brazilian Health Regulatory Agency (Anvisa) (BR) & Yoko Hirabayashi, National Institute of Health Sciences (NIHS) (JP)			
08:30- 08:40	Opening Remarks	Co-chairs	
08:40- 09:00	Non-Targeted Analysis Q&A	Dingyi Yu, Singapore Food Agency (SFA) (SG)	
09:00- 09:20	Emerging technologies in vaccines Q&A	Manuela Mura, European Medicines Agency (EMA)	
09:20- 09:40	Advancing Regulatory Science thru Innovation- Microphysiological Systems Q&A	Suzanne Fitzpatrick, FDA (US)	
09:40- 10:00	The Ascent of AI: Predicting Drug-Induced Liver Injury (DILI) Q&A	Weida Tong, FDA (US)	
10:00- 10:20	Safety assessment of cell-based therapeutic products derived from iPS cells Q&A	Satoshi Yasuda, National Institute of Health Sciences (NIHS) (JP)	
10:20- 10:40	Coffee/Tea break		
	5 Artificial Intelligence /Machine Learning : Maurice Whelan, European Commission (EC, JRC) & Weida Te	ong, FDA (US)	
10:40- 10:50	Opening Remarks	Co-chairs	
10:50- 11:10	Newly developed artificial intelligence (AI) based bioimaging inspection system for lymph-node granuloma lesions in high-speed line slaughter plants Q&A	Annamalai Manickavasagan, Bioimaging	







		Research Solutions (CA)
11:10- 11:30	Of Mice and Machines: Augmented Intelligence for Improving Chemical Safety Assessments Q&A	Nicole Kleinstreuer, NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) (US)
11:30- 11:50	GCRSR Interagency LLMs Taskforce: the Progress Report and Beyond Q&A	Joshua Xu, FDA (US)
11:50- 12:10	AskYourDocs: harnessing the power of LLMs for a working cross-agency prototype on Information Retrieval from PDFs Q&A	Nicolas Löffler- Pérez, Swissmedic (CH)
12:10- 12:30	Molecular Representation for Drug Safety Assessment Q&A	Djork-Arné Clevert, Pfizer (DE)
12:30- 13:30	Networking lunch	1
Co-chairs:	6 Horizon scanning I : Supriya Sharma, Health Canada (CA)& Bo Li, National Institut trol (NIFDC) (CN)	es for Food and
13:30- 13:40	Opening Remarks	Co-chairs
13:40- 14:00	Structural analysis of therapeutic antibodies using CRYO EM Q&A	Masato Kiyoshi, National Institute of Health Sciences (NIHS) (JP)
14:00- 14:20	An evidence pathway for trustworthy AI innovations: bridging the gap between developer and user communities Q&A	Claudius Griesinger (EC, JRC)
14:20- 14:40	TK Plate, an open access platform for TK and TD modelling Q&A	Jean Lou Dorne, EFSA







14:40- 15:00	Navigating Regulatory Genomics: Applications, Strengths, and Limitations in Monitoring Threats in the Food Supply Chain Q&A	Catherine Carrillo, Canadian Food Inspection Agency (CIFA) (CA)	
15:00- 15:15	Short Coffee/Tea break		
SESSION 7 Horizon scanning II Co-chairs: Marta Hugas, former Chief Scientist, EFSA & Bill Slikker, former Director, NCTR, FDA (US)			
15:15- 15:25	Opening Remarks	Co-chairs	
15:25- 15:45	Innovation in Regulatory Science Awards at Burroughs Wellcome Fund—Preview of the Latest Technologies and Progress Towards Equitable Clinical Outcomes Q&A	Tammy Collins, Burroughs Wellcome Fund (US)	
15:45- 16:05	Toward social implementation and regulatory acceptance of MPS Q&A	Daiju Yamazaki, National Institute of Health Sciences (NIHS) (JP)	
16:05- 16:25	Development status and supervision of organoids and organ-on-a-chip in China Q&A	Xingchao Geng, National institutes for Food and Drug Control (NIFDC), (CN)	
16:25- 16:45	Closing remarks	Georges Kass, EFSA Weida Tong, FDA, US Carlos das Neves, EFSA	